2025 Leerink Partners 2025 Global Healthcare Conference at 8:00 a.m. ET on Tuesday, March 11, 2025 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https ...

After two weeks of sleepless nights, growing comfort with conference calls and "esprit de corps," Regeneron researchers are making headway toward a COVID-19 therapy with the backing of ...

Sanofi and Regeneron said that drug candidate Itepekimab didn’t meet primary endpoint in a phase three study, although a ...

TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 financial and operating ...

Regeneron will present new and updated data on its oncology and hematology portfolio at the prestigious 2025 ASCO Annual Meeting, highlighting its commitment to research in difficult-to-treat cancers.

Regeneron presented 12-month data from the LINKER-MM1 study with a cutoff date of Sept. 8, 2023 at the American Association for Cancer Research meeting April 7. Patients with multiple myeloma who ...

A replay of the conference call and webcast will be archived on the company's website for at least 30 days. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and ...

TARRYTOWN, N.Y., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announces the following September 2024 investor events: Investor Conference Presentations • Morgan ...